TY  - JOUR
AU  - Aguado, Cristina
AU  - Giménez-Capitán, Ana
AU  - Karachaliou, Niki
AU  - Pérez-Rosado, Ana
AU  - Viteri, Santiago
AU  - Morales-Espinosa, Daniela
AU  - Rosell, Rafael
PY  - 2016
TI  - Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients
JF  - Translational Lung Cancer Research; Vol 5, No 5 (October 31, 2016): Translational Lung Cancer Research (Liquid Biopsy in Lung Cancer)<sup>1</sup>
Y2  - 2016
KW  - 
N2  - Obtaining a biopsy of solid tumors requires invasive procedures that strongly limit patient compliance. In contrast, a blood extraction is safe, can be performed at many time points during the course disease and encourages appropriate therapy modifications, potentially improving the patient’s clinical outcome and quality of life. Fusion of the tyrosine kinase genes anaplastic lymphoma kinase ( ALK ), C-ROS oncogen 1 ( ROS 1 ), rearranged during transfection ( RET ) and neurotrophic tyrosine kinase 1 ( NTRK1 ) occur in 1–5% of lung adenocarcinomas and constitute therapeutic targets for tyrosine kinase inhibitors. In addition, a  MET  splicing variant of exon 14, has been reported in 2–4% of lung adenocarcinoma and recent studies suggests that targeted therapies inhibiting  MET  signaling would be beneficial for patients with this alteration. In this review, we will summarize the new techniques recently developed to detect  ALK ,  RET ,  ROS  and  NTRK1  fusions and  MET  exon 14 splicing variant in liquid biopsy using plasma, serum, circulating tumor cells (CTCs), platelets and exosomes as starting material.
UR  - https://tlcr.amegroups.org/article/view/10083